- Home
- YI vs BCAB Comparison
YI vs BCAB Comparison
Compare YI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- BCAB
- Stock Information
- Founded
- YI 2010
- BCAB 2007
- Country
- YI China
- BCAB United States
- Employees
- YI N/A
- BCAB N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- YI Consumer Staples
- BCAB Health Care
- Exchange
- YI Nasdaq
- BCAB Nasdaq
- Market Cap
- YI 38.1M
- BCAB 40.5M
- IPO Year
- YI N/A
- BCAB 2020
- Fundamental
- Price
- YI $4.34
- BCAB $0.63
- Analyst Decision
- YI
- BCAB Hold
- Analyst Count
- YI 0
- BCAB 3
- Target Price
- YI N/A
- BCAB $1.00
- AVG Volume (30 Days)
- YI 10.3K
- BCAB 1.3M
- Earning Date
- YI 11-26-2025
- BCAB 11-13-2025
- Dividend Yield
- YI N/A
- BCAB N/A
- EPS Growth
- YI N/A
- BCAB N/A
- EPS
- YI N/A
- BCAB N/A
- Revenue
- YI $1,979,883,442.00
- BCAB $11,000,000.00
- Revenue This Year
- YI N/A
- BCAB N/A
- Revenue Next Year
- YI N/A
- BCAB N/A
- P/E Ratio
- YI N/A
- BCAB N/A
- Revenue Growth
- YI N/A
- BCAB N/A
- 52 Week Low
- YI $4.15
- BCAB $0.24
- 52 Week High
- YI $11.35
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- YI 37.45
- BCAB 43.83
- Support Level
- YI $4.20
- BCAB $0.61
- Resistance Level
- YI $4.43
- BCAB $0.69
- Average True Range (ATR)
- YI 0.16
- BCAB 0.08
- MACD
- YI 0.05
- BCAB -0.02
- Stochastic Oscillator
- YI 23.28
- BCAB 13.00
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.